The insulin-like growth factor binding proteins 3 and 7 are associated with colorectal cancer and liver metastasis

Over the last few decades, a great deal of attention has been directed to the IGF system for its vital role in regulating cell and tissue survival, growth and differentiation. The insulin-like growth factor binding proteins (IGFBPs), a main constituent of this system, have been implicated in the tumorigenesis of colorectal cancer (CRC). In this study, we intended to shed more light on two essential members; IGFBP3 as representative for the six main IGFBPs and IGFBP7 to represent their related proteins (IGFBP-rps). Our experiments on silencing IGFBP3 or IGFBP7 in the two human CRC cell lines SW480, Caco2, and in the rat CRC cell line CC531 show reduced proliferation, colony formation, and for IGFBP3, also reduced migration. The expression of both genes in 68 human CRC samples was higher in UICC stages II and III than in stages I and IV. Additionally, IGFBP3 was negatively correlated with age (p = 0.05) and positively related to IGFBP7 expression (p = 0.0001). Further, in a liver metastasis experiment, the expression of both genes was drastically increased in response to early metastatic growth in vivo. Since these high levels returned gradually to normal thereafter, it could be assumed that the up-regulation of IGFBPs is vital during the process of homing into the liver and early metastatic dissemination. Our results indicate that IGFBP3 and 7 cannot be simply considered as tumor suppressors but have additional properties, which become evident only during cancer progression and metastasis formation.

[1]  H. Adwan,et al.  Regulation of osteopontin and related proteins in rat CC531 colorectal cancer cells. , 2010, International journal of oncology.

[2]  W. Ruan,et al.  HSP60, a protein downregulated by IGFBP7 in colorectal carcinoma , 2010, Journal of experimental & clinical cancer research : CR.

[3]  Hiroyuki Yamamoto,et al.  IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. , 2010, Carcinogenesis.

[4]  W. Cohick,et al.  Endogenous IGFBP‐3 is required for both growth factor‐stimulated cell proliferation and cytokine‐induced apoptosis in mammary epithelial cells , 2009, Journal of cellular physiology.

[5]  T. Mikkelsen,et al.  Insulin-like growth factor binding protein 7 mediates glioma cell growth and migration. , 2008, Neoplasia.

[6]  W. Ruan,et al.  Tumor suppressor gene insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) induces senescence-like growth arrest in colorectal cancer cells. , 2008, Experimental and molecular pathology.

[7]  C. Belda-Iniesta,et al.  EGFR and colon cancer: a clinical view , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[8]  J. Park.  Inhibition of colon cancer cell growth by dietary components: role of the insulin-like growth factor (IGF) system. , 2008, Asia Pacific journal of clinical nutrition.

[9]  S. Ogino,et al.  IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53. , 2007, Neoplasia.

[10]  K. Hemminki,et al.  Insulin pathway related genes and risk of colorectal cancer: INSR promoter polymorphism shows a protective effect. , 2007, Endocrine-related cancer.

[11]  Jeffrey W. Clark,et al.  CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma , 2007, Virchows Archiv.

[12]  Huixin Hu,et al.  IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1 , 2006, Journal of Zhejiang University SCIENCE B.

[13]  A. Seifalian,et al.  The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge , 2005, International Journal of Colorectal Disease.

[14]  B. Henderson,et al.  Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): the multiethnic cohort. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[15]  R. Whelan,et al.  Insulin-like growth factor-binding protein 3 inhibits growth of experimental colocarcinoma. , 2004, Surgery.

[16]  M. Lai,et al.  Detection of the differentially expressed gene IGF-binding protein-related protein-1 and analysis of its relationship to fasting glucose in Chinese colorectal cancer patients. , 2004, Endocrine-related cancer.

[17]  H. Adwan,et al.  Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells , 2004, Cancer Gene Therapy.

[18]  R. Krajcik,et al.  Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[19]  P. Cohen,et al.  Nuclear effects: unexpected intracellular actions of insulin-like growth factor binding protein-3. , 2002, The Journal of endocrinology.

[20]  S. Mohan,et al.  IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. , 2002, The Journal of endocrinology.

[21]  M. Poot,et al.  Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. , 2002, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[22]  E. Riboli,et al.  Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden , 2002, Gut.

[23]  M. Samson,et al.  Vitamin D deficiency, muscle function, and falls in elderly people. , 2002, The American journal of clinical nutrition.

[24]  M. Rechler,et al.  Insulin-like Growth Factor (IGF)-binding Protein-3 Mutants That Do Not Bind IGF-I or IGF-II Stimulate Apoptosis in Human Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.

[25]  M. Stampfer,et al.  Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. , 2002, Journal of the National Cancer Institute.

[26]  D. Carbone,et al.  Expression of angiomodulin (tumor‐derived adhesion factor/mac25) in invading tumor cells correlates with poor prognosis in human colorectal cancer , 2001, International journal of cancer.

[27]  R. Baxter.  Signalling pathways involved in antiproliferative effects of IGFBP-3: a review , 2001, Molecular pathology : MP.

[28]  J. Clifford,et al.  Direct Functional Interactions between Insulin-like Growth Factor-binding Protein-3 and Retinoid X Receptor-α Regulate Transcriptional Signaling and Apoptosis* , 2000, The Journal of Biological Chemistry.

[29]  E. Riboli,et al.  Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. , 2000, Journal of the National Cancer Institute.

[30]  P. Cohen,et al.  Role of insulin‐like growth factors and their binding proteins in growth control and carcinogenesis , 2000, Journal of cellular physiology.

[31]  T. A. Serel,et al.  Serum insulin-like growth factor is not a useful marker of prostate cancer. , 2000, BJU international.

[32]  J. Rosenbloom,et al.  IGFBP-3 mediates TGF-beta1-induced cell growth in human airway smooth muscle cells. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[33]  Mitsuo Kato.  A Secreted Tumor-Suppressor, mac25, with Activin-Binding Activity , 2000, Molecular medicine.

[34]  J. Kawai,et al.  Methylation and downregulated expression of mac25/insulin-like growth factor binding protein-7 is associated with liver tumorigenesis in SV40T/t antigen transgenic mice, screened by restriction landmark genomic scanning for methylation (RLGS-M). , 2000, Biochemical and biophysical research communications.

[35]  E. Friedman,et al.  IGFBP-3 mediates TGF beta 1 proliferative response in colon cancer cells. , 2000, International journal of cancer.

[36]  C. Paraskeva,et al.  Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. , 2000, Cancer research.

[37]  V. Hwa,et al.  The Insulin-like Growth Factor-binding Protein (igfbp) Superfamily* , 2022 .

[38]  J. Blahovec,et al.  Insulin-like growth factor binding proteins and their functions (minireview). , 1999, Endocrine regulations.

[39]  R. Rosenfeld,et al.  Insulin-like growth factor binding proteins (IGFBPs) and IGFBP-related protein 1-levels in cerebrospinal fluid of children with acute lymphoblastic leukemia. , 1999, The Journal of clinical endocrinology and metabolism.

[40]  S. Mohan,et al.  Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily. , 1998, The Journal of clinical endocrinology and metabolism.

[41]  B. Peterkofsky,et al.  Phosphorylation of rat insulin-like growth factor binding protein-1 does not affect its biological properties. , 1998, Archives of biochemistry and biophysics.

[42]  P. Newcomb,et al.  Insulin-like Growth Factor-binding Protein (IGFBP-3) Predisposes Breast Cancer Cells to Programmed Cell Death in a Non-IGF-dependent Manner* , 1997, The Journal of Biological Chemistry.

[43]  S. Leal,et al.  The Type V Transforming Growth Factor β Receptor Is the Putative Insulin-like Growth Factor-binding Protein 3 Receptor* , 1997, The Journal of Biological Chemistry.

[44]  T. Nam,et al.  Insulin-like growth factor binding protein-5 binds to plasminogen activator inhibitor-I. , 1997, Endocrinology.

[45]  C. Stewart,et al.  Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. , 1996, Physiological reviews.

[46]  S. Velasco-Miguel,et al.  Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.

[47]  M. Ulshen,et al.  Regulation and localization of the insulin-like growth factor system in small bowel during altered nutrient status. , 1995, The American journal of physiology.

[48]  M. Murphy,et al.  Identification and characterization of genes differentially expressed in meningiomas. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[49]  D. Bikle.  Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. , 1992, Endocrine reviews.

[50]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.